
Sign up to save your podcasts
Or
In this week's episode we’ll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia.
Featured Articles:
4.1
4848 ratings
In this week's episode we’ll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia.
Featured Articles:
129 Listeners
71 Listeners
319 Listeners
26 Listeners
489 Listeners
273 Listeners
2 Listeners
186 Listeners
362 Listeners
3 Listeners
2 Listeners
29 Listeners
165 Listeners
48 Listeners
1 Listeners